Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Specific GIST Mutation Subsets
NCT06087263Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2024
- Primary completion
- Jul 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in gastrointestinal stromal tumor (GIST), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2024; status: active, not recruiting.
02
Drugs
regorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT06087263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087263.